Grilley, a pharmacist by training, spoke with ScienceBoard.net at ISCT22 about the evolution of the CGT industry which is driving clinical translation of CGTs that are benefitting patients.

"Now that there's approved CGT products on the market, that's a whole other world," said Grilley, who is also chair of ISCT's North American Legal and Regulatory Affairs Committee. "My first ISCT meeting was Dublin, which I think was 22 years ago, and at that meeting, obviously, we were all talking science ... and now, we're talking about successful launches and trying to standardize the way products are released so that when you have [chimeric antigen receptor] CAR T cells there's not different rules for different products -- and all the sites that are using these products are trying to figure that all out."

Watch the video below to learn more.

Galipeau to replace Levine as ISCT president
Dr. Jacques Galipeau, associate dean for therapeutics development at the University of Wisconsin-Madison, is set to replace Bruce Levine, PhD, professor...

ISCT22: RoosterBio, ShiftBio partner to harness the power of MSCs, exosomes
RoosterBio, a supplier of human mesenchymal stem/stromal cells (MSCs), recently announced a strategic partnership with ShiftBio, a South Korean company...

ISCT22: Scale up of cell therapy manufacturing is a significant, but addressable challenge
The cell therapy industry is facing a significant but addressable challenge when it comes to scaling up manufacturing, according to Bob Newman, PhD, chief...

ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with ScienceBoard.net at the International Society for Cell & Gene Therapy (ISCT)...

ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis,...

ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes...

ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic...

ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...

ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...

ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with ScienceBoard.net...

ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...